News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,126 Results
Type
Article (13818)
Company Profile (101)
Press Release (252207)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (88081)
Career Advice (465)
Deals (15349)
Drug Delivery (67)
Drug Development (36614)
Employer Resources (49)
FDA (6299)
Job Trends (6202)
News (150277)
Policy (14045)
Tag
Academia (441)
Accelerated approval (2)
Adcomms (6)
Allergies (36)
Alliances (23239)
ALS (37)
Alzheimer's disease (394)
Antibody-drug conjugate (ADC) (42)
Approvals (6339)
Artificial intelligence (113)
Autoimmune disease (9)
Automation (4)
Bankruptcy (149)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (40)
Bladder cancer (22)
Brain cancer (16)
Breast cancer (83)
Cancer (645)
Cardiovascular disease (72)
Career advice (409)
Career pathing (12)
CAR-T (23)
Cell therapy (90)
Cervical cancer (4)
Clinical research (30951)
Collaboration (352)
Compensation (159)
Complete response letters (17)
COVID-19 (759)
CRISPR (22)
C-suite (128)
Cystic fibrosis (37)
Data (667)
Denatured (15)
Depression (10)
Diabetes (83)
Diagnostics (1325)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (61)
Drug pricing (66)
Drug shortages (12)
Duchenne muscular dystrophy (37)
Earnings (32247)
Editorial (12)
Employer branding (4)
Employer resources (43)
Events (37621)
Executive appointments (400)
FDA (6741)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (217)
Gene editing (40)
Generative AI (9)
Gene therapy (101)
GLP-1 (350)
Government (1301)
Grass and pollen (3)
Guidances (23)
Healthcare (3564)
Huntington's disease (4)
IgA nephropathy (12)
Immunology and inflammation (35)
Indications (14)
Infectious disease (794)
Inflammatory bowel disease (56)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (48)
Interviews (59)
IPO (5885)
IRA (29)
Job creations (2051)
Job search strategy (373)
Kidney cancer (6)
Labor market (12)
Layoffs (181)
Leadership (4)
Legal (3433)
Liver cancer (19)
Lung cancer (87)
Lymphoma (57)
Machine learning (2)
Management (16)
Manufacturing (163)
MASH (34)
Medical device (1277)
Medtech (1279)
Mergers & acquisitions (9675)
Metabolic disorders (267)
Multiple sclerosis (21)
NASH (14)
Neurodegenerative disease (24)
Neuropsychiatric disorders (8)
Neuroscience (584)
NextGen: Class of 2025 (1586)
Non-profit (595)
Now hiring (8)
Obesity (152)
Opinion (119)
Ovarian cancer (22)
Pain (54)
Pancreatic cancer (15)
Parkinson's disease (47)
Partnered (7)
Patents (121)
Patient recruitment (30)
Peanut (10)
People (28990)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8059)
Phase II (13097)
Phase III (11748)
Pipeline (471)
Policy (72)
Postmarket research (1401)
Preclinical (3230)
Press Release (25)
Prostate cancer (48)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (170)
Real estate (2638)
Recruiting (17)
Regulatory (10141)
Reports (14)
Research institute (567)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (8)
Schizophrenia (37)
Series A (38)
Series B (13)
Service/supplier (3)
Sickle cell disease (32)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1629)
State (2)
Stomach cancer (3)
Supply chain (32)
Tariffs (32)
The Weekly (30)
Vaccines (157)
Venture capitalists (14)
Weight loss (100)
Women's health (8)
Worklife (4)
Date
Last 7 days (283)
Last 30 days (852)
Last 365 days (11679)
2025 (3931)
2024 (12510)
2023 (14256)
2022 (19575)
2021 (20084)
2020 (19032)
2019 (14885)
2018 (11713)
2017 (13888)
2016 (13130)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (57)
Arkansas (3)
Asia (20150)
Australia (2616)
California (1786)
Canada (932)
China (248)
Colorado (71)
Connecticut (70)
Delaware (61)
Europe (39576)
Florida (341)
Georgia (39)
Idaho (9)
Illinois (203)
India (16)
Indiana (137)
Iowa (1)
Japan (96)
Kansas (58)
Kentucky (13)
Louisiana (1)
Maine (2)
Maryland (264)
Massachusetts (1538)
Michigan (30)
Minnesota (96)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (8)
New Hampshire (6)
New Jersey (787)
New Mexico (7)
New York (533)
North Carolina (404)
North Dakota (2)
Northern California (733)
Ohio (51)
Oklahoma (4)
Oregon (16)
Pennsylvania (460)
Puerto Rico (8)
Rhode Island (10)
South America (502)
South Carolina (2)
Southern California (751)
Tennessee (34)
Texas (237)
United States (7467)
Utah (34)
Virginia (79)
Washington D.C. (31)
Washington State (124)
Wisconsin (17)
266,126 Results for "thetis pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Thetis Pharmaceuticals Presents New Preclinical and Clinical Data for TP-317 at ECCO 2025
February 19, 2025
·
3 min read
Press Releases
Thetis Pharmaceuticals Announces Appointment of Fabio Cataldi, M.D., to Board of Managers and Scientific Advisory Board
November 14, 2024
·
1 min read
Press Releases
Thetis Pharmaceuticals Announces Positive Initial Results From Phase 1a Study of TP-317 in Healthy Subjects
October 31, 2024
·
2 min read
Press Releases
Thetis Pharmaceuticals Secures an Additional $8.975 Million in Program-Related Investment Funds from the Helmsley Charitable Trust to Advance TP-317, an Oral BLT1 Agonist, into a Phase 1b Trial in Ulcerative Colitis Patients
January 9, 2025
·
3 min read
Mario Sznol, MD, Leader of the Melanoma Clinical Research Team at the Yale Cancer Center, Joins Thetis Pharmaceuticals Scientific Advisory Board
Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing a first-in-class small molecule ChemR23 agonist to treat cancer and autoimmune diseases small molecule (TP-317) to treat cancer and autoimmune diseases
November 7, 2023
·
4 min read
Business
Thetis Pharmaceuticals Launches Resolvin E1 Cancer Program and Scientific Advisory Board
Thetis Pharmaceuticals LLC (“Thetis”), a privately-held biopharmaceutical company developing Resolvin-based therapies, announced today the launch of a new program in cancer and the formation of a scientific advisory board (SAB) with several prominent cancer researchers and industry veterans.
July 8, 2021
·
4 min read
Drug Development
Thetis Pharmaceuticals Receives Orphan Drug Designation from FDA for Resolvin E1 Therapy for Pancreatic Cancer
Thetis Pharmaceuticals (“Thetis”), a leading developer of Resolvin-based therapies for cancer and autoimmune diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to TP-317 for treatment of pancreatic cancer.
July 28, 2021
·
6 min read
Drug Development
Trust, Tech, and Tomorrow: A Pharmaceutical Executive’s WEF Insights
Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.
March 5, 2025
·
1 min read
·
Lori Ellis
Mergers & acquisitions
Taiho Pharmaceutical Buys ADC Partner Araris for up to $1.1B Total
Japan-based Taiho Pharmaceutical has worked with Araris Biotech since 2023 developing antibody-drug conjugates for the oncology space.
March 17, 2025
·
2 min read
·
Dan Samorodnitsky
Drug Development
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
Achilles Therapeutics plc announced interim Phase I/IIa data on the use of clonal neoantigen reactive T cells from the CHIRON study in advanced unresectable or metastatic non-small cell lung cancer and the THETIS study in recurrent or metastatic malignant melanoma.
April 4, 2024
·
6 min read
1 of 26,613
Next
